Source: http://www.prnewswire.com/
RAANANA, Israel, Jan. 5, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced the Company intends to pursue Sjögren's syndrome as the second indication for its lead drug candidate hCDR1. Currently in development for the treatment of systemic lupus erythematosus (SLE), hCDR1 has been tested in over 400 patients, and is set to enter a global Phase 2 trial for SLE.
New in-vitro data from studies evaluating cells obtained from serum samples of patients with Sjögren's syndrome demonstrate that incubation with hCDR1 resulted in a significant reduction of gene expression of three cytokines considered to be pathogenic in Sjögren's syndrome. These data correspond to some of the in vitro data obtained in studies testing serum samples from patients with SLE.
Read more: http://www.prnewswire.com/news-releases/xtl-biopharmaceuticals-preclinical-studies-of-hcdr1-demonstrate-therapeutic-potental-in-the-treatment-of-sjogrens-syndrome-300386273.html